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Introduction
Since its first electrocardiographic description in 1909, atrial fi-
brillation (AF) has been recognized as a common arrhythmia, and 
more recently it has been associated with increased cardiovascular 
morbidity and mortality. With a prevalence of 1% among the adult 
population, AF is the most common arrhythmia that requires treat-
ment. Current treatment guidelines recommend long-term oral an-
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{mean age 63.6±12.2 years, male 3150 (56.1%)} in 27 hospitals from Jan. 2001 to Oct. 2007 were reviewed.
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sixties (1852 patients) accounted for about one third of patients studied. As patients grew older, INR increased and VKA dosage decreased. 
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ticoagulation with a vitamin K antagonist (VKA), such as warfarin, 
that is targeted at an international normalized ratio (INR) of 2.5 
(range, 2.0 to 3.0) in patients with AF who are at a moderate to high 
risk of stroke based on the presence of two or more of the following 
risk factors: 1) age >75 years; 2) history of hypertension; 3) diabetes 
mellitus; and 4) moderately or severely impaired left ventricular sys-
tolic function and/or heart failure.
1)2) However anticoagulants can 
cause severe adverse events, and physicians should therefore moni-
tor the INR of patients taking these drugs to ensure that their ra-
tios fall within a target range.
3) Furthermore, anticoagulation with 
VKAs has many limitations. VKAs offer a narrow therapeutic range 
of INR of 2.0-3.0; consequently, when INR levels fall below this tar-
get range, patients are at an increased risk of ischemic stroke, and 
when they exceed 3.0, the risk of bleeding is increased. Therefore, fre-
quent INR monitoring and dose adjustments are required. Further-
more, anticoagulation intensity can be influenced by multiple drug 
and food interactions, as well as by alcohol consumption. Therefore, 
patients taking VKAs have to be cautious about concomitant drug 
use and adhere to dietary and lifestyle restrictions.
4) As Western co-
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an increasing prevalence of obesity, the number of patients with AF 
is expected to rise sharply over the next 50 years.
5) There are racial/
ethnic differences in the prevalence of certain polymorphisms in 
genes that influence warfarin pharmacokinetics and pharmacody-
namics (e.g. cytochrome P450 2C9 and vitamin K epoxide reductase). 
The Asian population generally appears to require the lowest daily 
dose of warfarin to maintain a given INR target, whereas the White 
population requires an intermediate daily dose and the Black pop-
ulation requires the highest daily dose.
6) Thus, estimating INR in the 
context of AF in Korea is important, however only a few studies of 
this kind have been conducted. We conducted a large multicenter 
survey of Korean patients with AF to determine trends in oral anti-
coagulation use. The aim of this study was to investigate the pro-
portion of patients with optimal range INR and the dosage of oral 
anti-coagulation to achieve the optimal range according to age and 
gender in the Korean population. 
Subjects and Methods
This retrospective KORean Atrial Fibrillation investigation (KORAF) 
was conducted with patient medical record information collected 
between January, 2000 and October, 2007 in 27 Korean hospitals. 
Patients eligible for inclusion were adults with documented AF who 
had been taking VKAs for at least 1 year and with INR monitoring 
for more than two occasions. We excluded data from patients who 
received antiplatelet medications with their anticoagulants. We 
studied average INR levels according to age and average dosage of 
oral anticoagulant. All statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS) version 15.0 for 
Windows (SPSS Inc., Chicago, IL, USA)
Results
In total, 5616 patients were included in this study. The mean age 
of the surveyed population was 63.5±12.3 years and 56.1% were 
male. Patients were divided into age groups: below 50, 50-59, 60-
69, 70-74, and over 75 years old. The average INR level was 2.04. 
There was a significant difference in INR level according to age gr-
oup (Table1). Fig. 1 shows that the mean INR level of older patients 
Table 1. Average international normalized ratio level according to age group
Total ≤49 50-59 60-69 70-74 75≤
Total (mg) 2.04±0.64 1.96±0.56 2.03±0.66 2.02±0.60 2.09±0.67 2.08±0.69
Male (mg) 2.03±0.62 1.93±0.58 2.03±0.68 2.02±0.60 2.08±0.59 2.07±0.65
Female (mg) 2.05±0.65 2.02±0.52 2.04±0.61 2.02±0.59 2.10±0.76 2.09±0.74
Table 2. Average dosage of oral anticoagulant according to age group
Total ≤49 50-59 60-69 70-74 75≤
Total (mg) 3.66±1.50 4.33±1.72 4.00±1.48 3.62±1.40 3.31±1.40 3.14±1.31
Male (mg) 3.73±1.48 4.33±1.58 4.05±1.51 3.67±1.40 3.39±1.36 3.13±1.27
Female (mg) 3.57±1.52 4.33±1.93 3.92±1.42 3.57±1.40 3.22±1.44 3.15±1.34
Fig. 1. Average INR level according to age group. The mean INR level of older 
patients was slightly higher than that of younger patients. INR: interna-
tional normalized ratio.
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Fig. 2. Average dosage of oral anticoagulant according to age group. There 
was significant difference in dosage of oral anticoagulant according to age 
group. OAC: oral anticoagulant.
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was slightly higher than that of younger patients. Generally, old age 
is a high risk for stroke, so physicians want to maintain a higher INR 
in older patients. The mean dosage of oral anticoagulant was 3.66± 
1.59 mg. There was significant difference in dosage of oral antico-
agulant according to age group (Table 2, Fig. 2). The dosage of oral 
anticoagulant decreased with increasing age. Table 3 and Fig. 3 show 
the average dosage of oral anticoagulant according to the INR gr-
oup. The dosage of oral anticoagulant in the lower INR group was 
higher than in the higher INR group. An average 3.89 mg of oral 
anticoagulant was prescribed to individuals with INR over 3.5 in the 
male group, denoting possible drug over-prescription. In contrast, an 
average of 3.48 mg of oral anticoagulant was prescribed to individ-
uals with INR 1-1.4, possibly indicating drug under-prescription. The 
proportion of individuals achieving an optimal INR level (2-3) was 
only 42.4% (Fig. 4). An INR of 1.5-2 was maintained in one-third of 
patients, while patients with INR below 2 accounted for more than 
half (51.3%) the cases studied. The proportion of individuals achiev-
ing optimal INR level was higher among younger women and older 
men (Table 4, Fig. 5). The dosage of oral anticoagulant to achieve an 
optimal INR level was 3.71 mg (Table 5, Fig. 6). With increasing age, 
the higher INR level was preserved with a lower dosage of oral an-
ticoagulant. The dosage of oral anticoagulant in men was slightly hi-
gher than in women, and as shown in Fig. 6, the difference gradu-
ally decreased with increasing age.
Discussion
This study provides insight into the proportion of individuals ach-
ieving optimal-range INR and oral anticoagulant dosage in Korean 
Table 3. Average dosage of oral anticoagulant according to international normalized ratio group
Total 1-1.4 1.5-1.9 2-2.4 2.5-2.9 3-3.4 3.5≤
Total (mg) 3.66±1.50 3.48±1.37 3.75±1.57 3.72±1.50 3.66±1.44 3.46±1.43 3.51±1.63
Male (mg) 3.72±1.48 3.48±1.31 3.85±1.57 3.77±1.47 3.71±1.47 3.55±1.46 3.89±1.63
Female (mg) 3.57±1.52 3.48±1.44 3.60±1.60 3.66±1.55 3.59±1.39 3.36±1.40 3.09±1.54
Table 4. Proportion of optimal international normalized ratio level (2-3) 
according to age group
Total ≤49 50-59 60-69 70-74 75≤
Total (%) 42.4 42.5 42.6 41.5 46.4 40.9
Male (%) 43.2 39.2 41.4 43.2 40.7 42.8
Female (%) 41.7 47.9 45.1 39.6 41.7 38.8
Fig. 3. Average dosage of oral anticoagulant according to INR group. The dos-
age of oral anticoagulant in the lower INR group was higher than that in 
higher INR group. INR: international normalized ratio.
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Fig. 5. Proportion of optimal INR level (2-3) according to age group. The 
proportion of individuals achieving optimal INR level was higher among 
younger women and older men. INR: international normalized ratio.
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patients with AF. Among Korean patients with AF on VKAs, less than 
half reached therapeutic range levels of INR and the mean dosage 
of oral anticoagulant was 3.66 mg, which decreased with increasing 
age. The dosage of oral anticoagulant to achieve optimal INR levels 
was 3.71 mg.
Almost all studies have shown that AF is a potent risk factor for 
stroke, increasing its risk by nearly 5- fold; adjusted dose warfarin 
reduced the annual rate of any stroke by 68%.
7)8) Besides antico-
agulant use, it is necessary to use medications for rate and rhythm 
control.
9) Compared with aspirin, oral anticoagulant use significantly 
decreases the risk of all strokes and cardiovascular events for pa-
tients with nonvalvular chronic or paroxysmal AF.
10) While the preval-
ence of AF was 0.4% in Korean individuals that were 40-69 years of 
age,
5) it may increase with the aging population rendering AF a pu-
blic health problem of major concern. 
This study was conducted as a large multicenter survey of Kore-
an patients with AF to gain insight into trends of oral anti-coagu-
lation use. The average INR level was 2.04 for AF patients. This level 
is within the therapeutic range for prevention of stroke. However, an 
optimal INR level (2-3) was achieved in only 42.4% of cases stud-
ied. In over half of the patients with AF, the INR value was out of 
range, especially in the sub-therapeutic range, which is of particu-
lar concern because of the increased risk of ischemic stroke. Sub-
therapeutic INR levels of less than 2.0 have been associated with 
more thromboembolic events and severe strokes.
11) In this study, the 
mean dosage of oral anticoagulant was 3.66 mg, which decreased 
with age. Age of greater than 80 years and perceived bleeding risk 
were the most often cited reasons for not prescribing warfarin.
12) For 
this reason, the proportion of optimal INR was higher in younger wo-
men and older men. With increasing age, dosage of oral anticoag-
ulant needed to achieve optimal INR level (2-3) decreased. Therefore, 
when physicians prescribe oral anticoagulants to older patients with 
AF, dosage of oral anticoagulant needs to be decreased relative to 
that given to younger patients with AF. However patients with sub-
therapeutic INR have an increased risk of ischemic stroke, hence 
frequent INR monitoring and dose adjustments are required in older 
patients with AF. Physicians should adjust their clinical practices ac-
cordingly by aggressively correcting sub-therapeutic INR and av-
oiding overreaction to INR that narrowly exceeds 3.
Non-whites are at greater risk for several subtypes of ischemic 
stroke; cardioembolic stroke attributable to AF is more frequently im-
plicated in Whites.
13) In a recent systematic review of 67 anticoagul-
ation studies (69% of which were for AF) by van Walraven et al.
14) 
patients were in the therapeutic range 63.6% of the time overall in 
the USA. The percent-time on warfarin did not differ by race and eth-
nicity. The same study reported that Whites, Hispanic, and Asians 
had similar achieved anticoagulation intensity, however Blacks 
spent more time in the sub-therapeutic range (INR <2), which likely 
contributed to the observed absence of stroke reduction. The me-
dian percent-time on warfarin when INR was 2 to 3 was 54.5% 
overall, but it was lower in Blacks at 47.8% while the other groups 
had a rate of about 54%.
6) 
In Japan, in order to prevent stroke in AF, lower INR (1.6-2.6) was 
recommended for elderly patients
15) and with a mean daily dose of 
warfarin of 2.68±0.95 mg, INR was 1.99±0.24. The INR did not cor-
relate with increasing age.
16) Moreover, warfarin was used extensive-
ly in patients with AF whose stroke risk was relatively low with half 
of them having CHADS2 scores of 0 to 1.
17) In Japan, lower INR val-
ues were recommended and the dose of warfarin was lower than in 
Korean patients.
This study showed that the dosage of oral anticoagulants that 
was needed to achieve an optimal INR level was 3.71 mg in Korean 
patients. The proportion of patients with optimal INR was lower 
than in other countries. An effort to maintain optimal INR there-
fore will be required.
There were several limitations in our study. This study had the 
inherent limitation of its retrospective nature. Various methods of 
patient recruitment were used in different hospitals; hence gener-
Table 5. Dosage of oral anticoagulant for optimal international normalized ratio level (2-3) according to age group
Total ≤49 50-59 60-69 70-74 75≤
Total (mg) 3.71±1.48 4.43±1.61 4.10±1.54 3.66±1.36 3.37±1.41 3.09±1.20
Male (mg) 3.75±1.47 4.44±1.56 4.11±1.57 3.70±1.33 3.43±1.39 3.12±1.21
Female (mg) 3.64±1.50 4.43±1.69 4.09±1.50 3.59±1.40 3.29±1.43 3.06±1.20
Fig. 6. Dosage of oral anticoagulant (OAC) for optimal international nor-
malized ratio level (2-3) according to age group. The dosage of oral antico-
agulant in men and women gradually decreased with increasing age.
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alizing among hospitals may be problematic. The relationship be-
tween INR level and rates of major adverse cardiac events was not 
studied. It is clear that much additional work will be required and it 
is hoped that this study will stimulate further investigation. Howev-
er, findings of this study should help reduce future cardiovascular 
disease events and better understand AF in Korea. 
In conclusion, in Korean patients with AF, less than half of the 
cases on oral anticoagulant reached the therapeutic range of INR. 
Mean dosage of VKA was 3.66±1.59 mg, and the dosage of oral an-
ticoagulant to achieve optimal INR level was 3.71 mg, which de-
creased with increasing age. 
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